Clinical trial
A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
NCT00215852 · AIM ImmunoTech Inc., Industry · Terminated
Key facts
| NCT number | NCT00215852 |
|---|---|
| Title | A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects |
| Official title | A Randomized, Dose-Ranging Study of Alferon® LDO [Low Dose Interferon Alfa-n3 (Human Leukocyte Derived)] in Asymptomatic HIV+ Subjects |
| Lead sponsor | AIM ImmunoTech Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Alferon LDO |
| Enrollment | 17 |
| Start date | Jul 1, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: